A quarterly review conducted on 4/17/18, identified that the written directive for administration of
Ra-223 was incorrect. The written directive stated that the
Ra-223 should be administered orally, but should have stated that it was to be administered intravenously (IV). The review determined that there was no impact to any patients as a result of the error in the written directive. The review identified one case where the written directive was used. However, the technician administered the
Ra-223 to the patient via IV and not orally.
The corrective actions taken by the licensee were to correct the written directive, and review the directive with the technician to understand why the technician did not consult with the physician when there was an error in the directive.
The licensee notified the NRC R3 Office (Warren).
A Medical Event may indicate potential problems in a medical facility's use of radioactive materials. It does not necessarily result in harm to the patient.